Bashan Dror 4

4 · Protalix BioTherapeutics, Inc. · Filed Jul 2, 2019

Insider Transaction Report

Form 4
Period: 2019-06-30
Bashan Dror
DirectorPRESIDENT AND CEO
Transactions
  • Award

    Stock Options (Right to Buy)

    2019-06-30+1,600,0001,600,000 total
    Exercise: $0.47Exp: 2029-06-30Common Stock (1,600,000 underlying)
Footnotes (1)
  • [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

Documents

1 file
  • 4
    tv524753_4.xmlPrimary

    OWNERSHIP DOCUMENT